AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03715712 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standardized blood pressure management
Description: Standardized blood pressure management of a mean blood pressure > 65mmHg and a systolic blood pressure of \< 160mmHg using norepinephrine continuous infusion
Study NCT03715712 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Individualized blood pressure management
Description: Individualized blood pressure management of 20% within the preoperative ward blood pressure using norepinephrine continuous infusion
Study NCT01771822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen 5% topical gel
Description: 0.2 ml applied daily for 21 days over 3 weeks under occlusive conditions
Study NCT01771822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical gel vehicle
Description: 0.2 ml applied daily for 21 days over 3 weeks under occlusive conditions
Study NCT01771822 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium lauryl sulfate 0.2%
Description: 0.2 ml applied daily for 21 days over 3 weeks under occlusive conditions
Study NCT01771822 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sodium chloride solution 0.9% (saline)
Description: 0.2 ml applied daily for 21 days over 3 weeks under occlusive conditions
Study NCT02478125 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Burixafor Hydrobromide
Description: Investigators will determine the kinetics of PCa cell release into the blood with four daily dosages of Burixafor hydrobromide alone or in combination with G-CSF
Study NCT02478125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Investigators will administer a single 75 mg/m2 IV dose of docetaxel. Twenty-one days later investigators will re-treat enrolled men with the optimal mobilization strategy + docetaxel IV. The second dose of docetaxel being given in combination with the optimal mobilization strategy will be chosen according to a standard 3+3 dose escalation schema, in which the dose of bruixafor +/- G-CSF will be held constant and the dose of docetaxel will escalate between three dose-levels: 1) docetaxel 30 mg/m2 IV, 2) docetaxel 60 mg/m2 IV, and 3) docetaxel 75 mg/m2
Study NCT02478125 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: G-CSF
Description: G-CSF will be given as a daily subcutaneous (SC) injection beginning 4 days prior to Burixafor hydrobromide and continuing through the 4 days of Burixafor hydrobromide treatment
Study NCT02139358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: The Phase I trial will start at the recommended phase II dose (RP2D) for gemcitabine but will have a de-escalation dose levels in the event that an unacceptable toxicity requires dose reduction. Dose level 0 = gemcitabine (1200 mg/m2) IV D1,8 q21 days; Dose level -1 = gemcitabine (1000 mg/m\^2) IV D1,8 q21 days; Dose level -2 = gemcitabine (850 mg/m\^2) IV D1,8 q21 days. The RP2D will be the dose level where 0-1 dose limiting toxicities (DLTs) in six patients occur.
Study NCT02139358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab will be given using an 8 mg/kg loading dose on cycle one, day one (C1D1), followed by 6 mg/kg IV on subsequent cycles every (q) 21 days.
Study NCT02139358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Pertuzumab will be given using an 840 mg IV loading dose on C1D1, followed by 420 mg IV on subsequent cycles q 21 days.
Study NCT04456335 — intervention group
Intervention type: GENETIC
Intervention: Collection of supragingival plaque from caries free children
Description: Supragingival plaque samples were collected from posterior molar teeth
Study NCT02965755 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Treatment recommendation
Description: Depending on the results from the participant's archival tissue, a panel of Johns Hopkins investigators will meet to interpret the molecular and genetic profiling results in order to identify any actionable mutations to provide a personalized treatment recommendation for the patient.
Study NCT01978080 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Kinesia HomeView
Study NCT01978080 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kinesia HomeView
Study NCT01602081 — intervention group
Intervention type: DEVICE
Intervention: reinforce soft tissue
Description: reinforce soft tissue
Study NCT01686581 — intervention group
Intervention type: DRUG
Intervention: botulinum toxin Type A
Description: Botulinum toxin Type A (BOTOX®) administered according to physician prescription.
Study NCT03758014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorogenic acid for Injection
Description: Chlorogenic acid (CHA) is a class 1 innovative small molecular natural drug, developed by Sichuan Jiuzhang Biological Science and Technology Co., Ltd. The mechanism of broad-spectrum antitumor activity is immunoregulation.
Study NCT03758014 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lomustine
Description: Lomustine (INN), abbreviated as CCNU (original brand name (formerly available) is CeeNU, now marketed as Gleostine), is an alkylating nitrosourea compound used in chemotherapy. It is closely related to semustine and is in the same family as streptozotocin. It is a highly lipid-soluble drug, thus it crosses the blood-brain barrier. This property makes it ideal for treating brain tumors, which is its primary use.
Study NCT05029024 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 30-minute mindful breathing
Description: The four exercises included identifying the in-and out-breath, following the entire length of the breath, bringing the mind back to the body and relaxing the whole body. Each exercise lasted 7.5 minutes.
Study NCT05029024 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: control group
Description: standard care alone
Study NCT00737412 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic: Bio-K+ CL1285
Description: The probiotic Bio-K+ CL1285 RX®, a mixture of Lactobacillus acidophilus and Lactobacillus casei, contains over 50 billion living bacteria per administered dose.
Study NCT00737412 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching capsules devoid of microorganisms
Study NCT02306122 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pharmacist calls patient unless physician cancels call
Study NCT02306122 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient nonadherence information sent to physician
Study NCT02306122 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pharmacist calls patient if physician requests call
Study NCT02306122 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Doctor receives information and may be allowed certain actions
Study NCT03387241 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone/ Formoterol
Description: See above
Study NCT03387241 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluticasone/ salmeterol
Description: See above
Study NCT02970253 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Capsular resection
Description: Capsular resection
Study NCT02970253 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Capsular retention
Description: Capsular retention
Study NCT04180735 — intervention group
Intervention type: PROCEDURE
Intervention: Liver transplantation
Description: Liver transplantation
Study NCT03028402 — intervention group
Intervention type: PROCEDURE
Intervention: C5-C6 arthrodesis
Description: A standard Smith Robinson anterior medial approach to the cervical spine. Vertebral endplates will be prepared by removing the cartilage endplate. Tricortical anterior iliac crest autografts will be harvested with a low-speed oscillating saw. Allografts will be fresh-frozen, vacuum-sealed, nonradiated tricortical grafts. All grafts will be fashioned in a typical Smith-Robinson formation. The motion segment will be distracted approximately 2-mm beyond the graft height before the insertion of each graft. Fusion plate will be contoured to cervical lordosis. Cervical plates will be positioned using surgical midline markers. All rigid anterior plate fixations will be performed using titanium anterior fixed-angle screw systems.
Study NCT02813746 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Fitness program
Study NCT02813746 — intervention group
Intervention type: BEHAVIORAL
Intervention: Stop smoking
Study NCT02813746 — intervention group
Intervention type: PROCEDURE
Intervention: Endometrial fluid collection
Study NCT02010801 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: irreversible electroporation
Study NCT02010801 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: nanoknife AngioDynamics US Ltd
Study NCT04535622 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A structured exercise
Description: Exercise training will be conducted by a physical therapist which will take about 10 to 15 minutes. Patient education will include how to keep face down in various postures, and how to actively exercise the related muscles and joints while maintaining face-down posture through video clip and brochure. Patients will go through three times of self-exercise sessions everyday according to the training provided to the patients. Active exercise for the FDP patients will include exercise in a hands and knees position, limb exercise in an FDP, and exercise in a standing position. The exercises were performed within the range of individual muscle strength and fitness.
Study NCT00116402 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluticasone and salmeterol
Description: 1. will start with fluticasone 220 mcg BID first and then crossover to combination therapy with salmeterol 50 mcg BID~2. will start with salmeterol 50 mcg BID first and then crossover to combination therapy with fluticasone 220 mcg BID.
Study NCT03545347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nandrolone Decanoate
Description: Injections every 3 weeks, last injection at week 12. Women 50 mg, men with total testosterone ≥ 11 nmol/l will receive 100 mg, and men with total testosterone \< 11 nmol/l will receive a dose of 200 mg.
Study NCT03545347 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein-rich nutritional supplement
Description: The protein-rich nutritional supplement is a liquid containing 18 g milk-based protein pr bottle. Patients will receive a minimum of 1.35 g/kg bodyweight/day); which means that most patients will receive 2 bottles per day for 12 weeks.
Study NCT03545347 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Protein-rich nutritional supplement
Description: The protein-rich nutritional supplement is a liquid containing 18 g milk-based protein pr bottle. Patients will receive a minimum of 1.35 g/kg bodyweight/day); which means that most patients will receive 2 bottles per day for 12 weeks.
Study NCT03545347 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical therapy
Description: The physical therapy intervention will include progressive strength training initiated daily on weekdays during hospitalization and continued twice per week in the outpatient rehabilitation program in the municipality (treatment as usual but with strength training as an obligatory component) for a total intervention period of 12 weeks from time of inclusion.
Study NCT03545347 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Physical therapy
Description: The physical therapy intervention will include progressive strength training initiated daily on weekdays during hospitalization and continued twice per week in the outpatient rehabilitation program in the municipality (treatment as usual but with strength training as an obligatory component) for a total intervention period of 12 weeks from time of inclusion.
Study NCT03545347 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride 9mg/ml Injection
Description: Placebo injection of 1 ml Sodium Chloride
Study NCT02520648 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neuro-lymphatic treatment
Description: The physical therapist applied direct firm rotary pressure, via thumb or tip finger, for 1 minute, from the transverse processes of T1 to the transverse processes of T12. To finish the intervention, hands were placed on the skull and sacrum during 2 minutes without movement.
Study NCT02349919 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo twice daily for 4 weeks
Study NCT03986788 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Weightlessness
Description: Volunteers will be studied during parabolic flight. Cerebral blood flow will be measured in different part of the brain during weightlessness ans compared to 1g and hypergravity measurements.
Study NCT02056457 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Responsible Fatherhood or Healthy Marriage Program
Description: RF grantees funded by the most recent re-authorization of the program must offer services in each of three categories: (1) healthy marriage; (2) responsible parenting; and (3) economic stability. HM grantees must provide one or more of eight allowable activities, which include marriage and relationship skills programs, mentoring, divorce reduction programs, and education in high schools on the value of marriage, relationships skills, and budgeting.
Study NCT02056457 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Other services in the community
Description: RF grantees funded by the most recent re-authorization of the program must offer services in each of three categories: (1) healthy marriage; (2) responsible parenting; and (3) economic stability. HM grantees must provide one or more of eight allowable activities, which include marriage and relationship skills programs, mentoring, divorce reduction programs, and education in high schools on the value of marriage, relationships skills, and budgeting.
Study NCT00744549 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lycopene, Vitamin D3, Selenium, Green Tea Extract, Vitamin E
Description: Twice a day with meals. Lycopene - 20 mg, Vitamin D3 - 200 IU, Selenium - 100 mcg, Green Tea Extract - 75 mg, Vitamin E - 50 IU
Study NCT00744549 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Twice a day with meals.
Study NCT02520648 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Articulatory spinal manual therapy
Description: Then the therapist performs pressures in the transverse apophysis from D1 to D12 (level of the paravertebral muscles, at a distance of 2 fingers of the spinous apophysis), applying sustained pressure during expiratory time until the articulatory barrier is reached.
Study NCT02520648 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Articulatory costal Manual therapy
Description: The therapist performs costal-vertebral articulatory movement, from 1st to 12th rib (level of the outside paravertebral muscles, at a distance of 4 fingers from the spinous apophysis on the back of the costal body) applying a sustained pressure during expiratory time and promoting its biomechanics, up to the articulatory barrier.
Study NCT03696797 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blood Donation
Description: Participants in the TREATMENT GROUP will have a Unit of blood (two cups, the same amount you would donate at the Red Cross) drawn. This involves having a needle inserted into a vein in your arm. Prior to taking the blood, staff will measure blood count to be sure participants are not anemic, and blood pressure to be sure there is no dehydration. During or after donation, participants will be given a sports drink to replace the fluid loss. Participants in the CONTROL GROUP will not donate blood, but will have a needle inserted into a vein in your arm. Neither group will not know to which they have been assigned, all will have a sleep mask (like a blindfold, covering the eyes, held on with an elastic band) placed so they will not know whether blood was actually removed.
Study NCT03696797 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Blood Donation
Description: Participants will have a needle inserted their arm, however, no blood will be drawn.
Study NCT01861522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bepotastine besilate
Description: Two TAU-284 5mg tablets will be taken orally twice a day
Study NCT01861522 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two Placebo tablets will be taken orally twice a day
Study NCT03421496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol Oral Solution
Description: An oral solution containing pharmaceutical grade cannabidiol (nonplant-based).
Study NCT02091986 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Symbicort pMDI
Description: Budesonide/formoterol pMDI 80/2.25 µg, 2 acuations twice daily
Study NCT02091986 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Symbicort pMDI
Description: Budesonide/formoterol pMDI 80/4.5µg, 2 acuations twice daily
Study NCT02091986 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide pMDI
Description: Budesonide pMDI 80µg, 2 acuations twice daily
Study NCT02136212 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Approach-positive AAT
Study NCT02136212 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control AAT
Study NCT02341495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferasirox
Description: Deferasirox (20mg/kg/day)on days 1-7 of protocol every 4 wks for 8 cycles PO
Study NCT02341495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol
Description: Cholecalciferol(4,000 units/day) on days 1-7 of protocol every 4 wks for 8 cycles PO
Study NCT02341495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Azacitidine (75mg/m2 subcutaneous or IV administration) on days 1-7 of protocol 28 days for 32 wks
Study NCT01190358 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sugar pill containing maltodextrin.
Study NCT01190358 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Grape seed extract
Description: Meganatural Gold® contains 300mg of grape seed extract.
Study NCT01679457 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TAU-ERP
Study NCT03175835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20 mg
Description: Treatment A: Rosuvastatin 20 mg(20 mg X 1 tablet) for Day1\~Day5
Study NCT03175835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-519 200 mg
Description: Treatment B: CKD-519 200 mg(100 mg X 2 tablets) for Day9\~Day21
Study NCT03175835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20 mg & CKD-519 200 mg
Description: Treatment C: Rosuvastatin 20 mg(20 mg X 1 tablet), CKD-519 200 mg(100 mg X 2 tablets) for Day22\~Day26
Study NCT03421496 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching oral solution
Study NCT03421496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vigabatrin
Description: Powder suspension
Study NCT03421496 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vigabatrin
Description: Powder suspension
Study NCT02716038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MPDL3280A
Description: MPDL3280A is a human, Fc optimized, monoclonal antibody directed against the protein ligand programmed cell death-1 ligand 1 (PD-L1), with potential immune checkpoint inhibitory and antineoplastic activities. Atezolizumab binds to PD-L1, blocking its binding to and activation of its receptor programmed death 1 (PD-1) expressed on activated T-cells, which may enhance the T-cell-mediated immune response to neoplasms and reverse T-cell inactivation. MPDL3280A 1200 mg will be administered as a 60 minute IV infusion on first administration, then over 30 minutes subsequently if tolerated.
Study NCT02716038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin is a second-generation platinum compound with a broad spectrum of antineoplastic properties. Carboplatin contains a platinum atom complexed with two ammonia groups and a cyclobutane-dicarboxyl residue. This agent is activated intracellularly to form reactive platinum complexes that bind to nucleophilic groups, thereby inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links. These carboplatin-induced DNA and protein effects result in apoptosis and cell growth inhibition. Carboplatin area under the curve (AUC)=6 will be administered as a 30 minute IV infusion immediately after nab-paclitaxel.
Study NCT02716038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Nab-paclitaxel is an albumin-stabilized nanoparticle formulation of the natural taxane paclitaxel with antineoplastic activity. Nab-paclitaxel binds to and stabilizes microtubules, preventing their depolymerization and so inhibiting cellular motility, mitosis, and replication. Nab-paclitaxel 100 mg/m2 will be administered as a 30 minute IV infusion.
Study NCT00550550 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo sublingual tablet, once daily
Study NCT00550550 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SCH 697243
Description: Grass sublingual tablet, once daily
Study NCT00550550 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Loratadine Syrup 1 mg/mL Rescue Treatment
Description: Loratadine Syrup 1 mg/mL was dosed orally once daily at a dose of 5 mg for children aged 5 to \<6 years of age and at a dose of 10 mg for children aged 6 to \<18 years of age as rescue medication for symptoms of rhinoconjunctivitis among participants with a total symptom score ≥4.